The Chinese Economy
In The Coronavirus Pandemic
China Institute, NYC (webinar)
At the present time, China is tirelessly fighting the coronavirus throughout the country. Cities are being locked down. A hospital is built in ten days. The national holiday is extended. And people are staying at home.
Live illustration :
(click to enlarge)
While China and the rest of the world firmly believe this epidemic will soon come to an end, it remains critical to analyze the impact it will have on the global economy. This current coronavirus has earned many comparisons to the 2003 SARS epidemic. Critics are predicting its economic impact will similarly be short-term (not affecting the medium- and long-term growth trend). However, with so many uncertainties, it is very difficult to determine what the coronavirus’ effect will ultimately be.
In spite of the current circumstances, we must ask – are there opportunities that can be generated from this epidemic? During the 2003 SARS epidemic, Jack Ma recognized online shopping as an economic pathway during a dire time. In 2020, are there new economic possibilities to be explored?
Please join China Institute and Cheung Kong Graduate School of Business America for a webinar, with expert economists and investors, where we will discuss:
How much has the hospitality industry already lost and how will they recover?
What percentage of small-to-medium businesses can survive after three months?
What are the newest government and bank policies to help businesses’ cash shortage? What’s the long-term impact on the economy?
How to seize the investing opportunities in the booming gaming and social-media industries?
What are the new business models born under the “stay-at-home” economy?
How is the epidemic helping 5G grow faster in China?
Live illustration by Sophie Ong / zovi
Event powered by China Institute
Kevin Chen is currently Chief Economist of Horizon Financial. Adjunct Associate Professor, New York University since Nov. 2012. A guest speaker at Harvard University, Fordham University, Pace University, and IESE Business School. Member of the Adjunct Advisory Committee of SPS, New York University. Interim Head of the Private Sector Concentration program of Ms. of Global Affairs, New York University. Member of the Economic Club of New York. Fellow of the Foreign Policy Association. Editorial Advisory Board Member of the Global Commodity Applied Research Digest (GCARD) at JP Morgan Center for Commodities (JPMCC) at the University of Colorado Denver Business School. Co-Chair of the New York Finance Forum. Fellow of International Center for Emerging Market Research, RUDN University in Moscow. Kevin is also a Co-Founder and Vice-Chairman of the Absolute Return Investment Management Association of China. Senior Portfolio Manager, Credit Agricole/Amundi Asset Management from Aug. 2008 to Oc. 2011. Director of Asset Allocation at Morgan Stanley August 2004 to August 2008. Manager at China Development Bank, September 1998 to August 2000. PhD in Finance from the Financial Asset Management Engineering Center at University of Lausanne, Switzerland at October 2004. Master’s degree in Finance, Center for Economic Research, Tilburg University in the Netherlands at August 2001. B.A. degree in Economics from the Renmin University of China in Beijing, China, July 1998.
Ken H. Swong, Director of institutional sales and investment strategist of Bank of China International
Kevin Xie is the President of Fosun Healthcare Holdings, Chairman and CEO of Overseas Healthcare Service Group and Chief Representative of Fosun U.S. office. In his current role, Mr. Xie is responsible for Fosun Group’s global healthcare investments in both primary and public market.
Prior to joining Fosun in 2015, Mr. Xie co-founded Locust Walk Capital, a global healthcare hedge fund. Before that, He served as the healthcare sector head at Scopia Capital, a multi-billion USD market neutral long-short equity hedge fund. He was a portfolio manager and managing director at Great Point Partners, a premier healthcare hedge fund / private equity fund.
Mr. Xie holds an MBA from The Wharton School, a Ph.D. in Chemistry from City University of New York, and a BS in Material Engineering from Tianjin University.